261 related articles for article (PubMed ID: 34307344)
1. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
[TBL] [Abstract][Full Text] [Related]
2. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
3. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
8. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
Ke J; Cui J; Yang X; Du X; Ma B; Yu L
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
[TBL] [Abstract][Full Text] [Related]
9. A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
Wang X; Zhao C; Huang D; Liu Z; Liu M; Lin F; Lu Y; Jia J; Lin L; Lin X; Li H; Chen Z
Front Immunol; 2022; 13():923533. PubMed ID: 35860262
[TBL] [Abstract][Full Text] [Related]
10. N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma.
Sun J; Ping Y; Huang J; Zeng B; Ji P; Li D
Front Cell Dev Biol; 2021; 9():705962. PubMed ID: 34422827
[TBL] [Abstract][Full Text] [Related]
11. HNRNPA2B1 inhibited SFRP2 and activated Wnt-β/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma.
Rong L; Xu Y; Zhang K; Jin L; Liu X
Pathol Res Pract; 2022 May; 233():153794. PubMed ID: 35364458
[TBL] [Abstract][Full Text] [Related]
12. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
[TBL] [Abstract][Full Text] [Related]
13. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.
Gao C; Li H; Ma W; Zhang Q; Liu C; Liu L; Zhuang J; Sun C
J Immunol Res; 2022; 2022():7519838. PubMed ID: 36061307
[TBL] [Abstract][Full Text] [Related]
15. RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
Liu J; Li Z; Cheang I; Li J; Zhou C
Front Genet; 2022; 13():777399. PubMed ID: 35154270
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
Li Y; Gu J; Xu F; Zhu Q; Chen Y; Ge D; Lu C
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33003204
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of the Transcriptome-wide m6A Methylome in Lung Adenocarcinoma by MeRIP Sequencing.
Mao W; Yu Q; Wang K; Ma Q; Zheng Y; Zhang G; Luo W; Wang N; Wang Y
Front Oncol; 2022; 12():791332. PubMed ID: 35903698
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine (m6A) regulator expression pattern correlates with the immune landscape in lung adenocarcinoma.
Wan RJ; Bai L; Jiang J; Hu CP; Chen Q; Zhao BR; Zhang Y; Li YY
Gene; 2022 Aug; 836():146639. PubMed ID: 35700805
[TBL] [Abstract][Full Text] [Related]
19. Function and prognostic value of N6-methyladenosine-modified RNAs in lung adenocarcinoma.
Liu J; Zheng Z; Zhong J
J Gene Med; 2023 Jan; 25(1):e3454. PubMed ID: 36282144
[TBL] [Abstract][Full Text] [Related]
20. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
Ye W; Huang T
PLoS One; 2022; 17(2):e0264384. PubMed ID: 35196365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
